A new frontier in targeted protein degradation
Targeted protein degradation has emerged as a powerful new drug modality with applications in a broad range of diseases. Until now, protein degradation efforts have focused on intracellular targets.
At Avilar, we are moving beyond the boundaries of the cell to pioneer the discovery and development of extracellular protein degraders. Our ATACs (ASGPR Targeting Chimeras) are a new class of protein degrader therapeutics that shuttle disease-causing proteins from the circulation to the endolysosome where they are degraded.
Our discovery platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. We are leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders.